摘要
骨质疏松症(OP)是一种骨代谢疾病,表现为骨形成减少和骨吸收增加,导致骨量丢失、骨组织微结构破坏,全身各处易于骨折。骨组织局部可表达肾素-血管紧张素系统(RAS)的主要成分并通过经典及非经典途径参与细胞氧化应激、增殖、分化及凋亡等过程。骨组织局部RAS过度激活时,一方面可以抑制成骨细胞分化或直接损伤其骨形成功能,另一方面促进破骨细胞分化和成熟,二者共同导致骨形成减少、骨吸收增加,参与OP发生。RAS抑制剂包括肾素抑制剂、血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂,已经被证实可以有效地拮抗RAS慢性激活时产生的病理效应,因此被认为是治疗OP的候选药物之一。
Osteoporosis is a bone metabolic disease,characterized by reduced bone formation and increased bone resorption that lead to loss of bone mass,microarchitecture changes in bone tissue and susceptibility to fracture. Bone tissue expresses the main components of the renin-angiotensin system(RAS),which is involved in many biological processes through classic and non-classic pathways,including oxidative stress,cell proliferation,differentiation,apoptosis. Excessive activation of the bone tissue RAS can inhibit osteoblast differentiation,damage its bone formation function directly,and promote osteoclast differentiation and maturation,leading to decreased bone formation and increased bone resorption,and inducing osteoporosis. RAS inhibitors include renin inhibitor,angiotensin converting enzyme inhibitor and angiotensinⅡ receptor blockers,which have been shown to antagonize pathological effects resulting from chronic activation of RAS effectively. Therefore,RAS inhibitors are considered one of the potential drugs for osteoporosis.
出处
《中国药理学与毒理学杂志》
CAS
CSCD
北大核心
2016年第10期1114-1119,共6页
Chinese Journal of Pharmacology and Toxicology
基金
国家自然科学基金(81220108026)
国家自然科学基金(81371940)~~
